Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis

Lupus

Volumn 21, Issue 9, 2012, Pages 959-968

  Martens, H A ^a   Nienhuis, H L A ^b   Gross, S ^b   Van Der Steege, G ^b   Brouwer, E ^b   Berden, J H M ^c   De Sevaux R G L ^c   Derksen, R H W M ^d   Voskuyl, A E ^e   Berger, S P ^f   Navis, G J ^b   Nolte, I M ^b   Kallenberg, C G M ^b   Bijl, M ^b  

^a Sint Maartenskliniek Nijmegen ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

lupus nephritis; polymorphisms; Receptor for advanced glycation end products; soluble receptor for advanced glycation end products; systemic lupus erythematosus

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC;

EID: 84863893585     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312444495     Document Type: Article

References (43)

1. De Leeuw K, Graaff R, de Vries R, et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2007 ; 46: 1551-1556 (Pubitemid 47500568)
2. De Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 2006 ; 15: 675-682 (Pubitemid 44682830)
3. Hein GE, Kohler M, Oelzner P, Stein G, Franke S. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int. 2005 ; 26: 137-141 (Pubitemid 41779823)
4. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008 ; 196: 9-21
5. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011 ; 13: R71 - R71
6. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev. 2010 ; 9: 661-665
7. He M, Kubo H, Morimoto K, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011 ; 12: 358-364
8. Friggeri A, Banerjee S, Biswas S, et al. Participation of the receptor for advanced glycation end products in efferocytosis. J Immunol. 2011 ; 186: 6191-6198
9. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002 ; 106: 2827-2835 (Pubitemid 35396983)
10. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998 ; 4: 1025-1031 (Pubitemid 28417334)
11. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'Angelo A. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc. 2006 ; 54: 1149-1150 (Pubitemid 43992560)
12. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1032-1037 (Pubitemid 40627851)
13. Nienhuis HL, de Leeuw K, Bijzet J, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford). 2008 ; 47: 1554-1558
14. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes. 1998 ; 47: 1155-1157 (Pubitemid 28294561)
15. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002 ; 3: 123-135 (Pubitemid 38961122)
16. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH. The functional - 374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes. 2003 ; 52: 891-894 (Pubitemid 36323601)
17. Jang Y, Kim JY, Kang SM, et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism. 2007 ; 56: 199-205 (Pubitemid 46074066)
18. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001 ; 50: 1505-1511 (Pubitemid 32500186)
19. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007 ; 25: 720-725 (Pubitemid 350223177)
20. Kalousova M, Jachymova M, Mestek O, et al. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant. 2007 ; 22: 2020-2026 (Pubitemid 47244776)
21. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
22. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006 ; 70: 732-742 (Pubitemid 44215349)
23. De Jong MM, Hofstra RM, Kooi KA, et al. No association between two MLH3 variants (S845G and P844L) and colorectal cancer risk. Cancer Genet Cytogenet. 2004 ; 152: 70-71 (Pubitemid 38757381)
24. Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol. 2010 ; 8: 86-92
25. McNair ED, Wells CR, Mabood QA, et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem. 2010 ; 341: 135-138
26. Kalousova M, Hodkova M, Kazderova M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006 ; 47: 406-411 (Pubitemid 43255173)
27. Leal SM, Ott J. Effects of stratification in the analysis of affected-sib-pair data: benefits and costs. Am J Hum Genet. 2000 ; 66: 567-575 (Pubitemid 30468835)
28. Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol. 2004 ; 16: 794-800 (Pubitemid 39423671)
29. Kankova K, Sebekova K. Genetic variability in the RAGE gene: possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications. Mol Nutr Food Res. 2005 ; 49: 700-709 (Pubitemid 41008208)
30. Falcone C, Geroldi D, Buzzi MP, et al. The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res. 2008 ; 39: 320-325
31. Kankova K, Marova I, Zahejsky J, et al. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism. 2001 ; 50: 1152-1160 (Pubitemid 33034698)
32. Martens HA, Nolte IM, van der SG, et al. An extensive screen of the HLA region reveals an independent association of HLA class I and class II with susceptibility for systemic lupus erythematosus. Scand J Rheumatol. 2009 ; 38: 256-262
33. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008 ; 40: 204-210 (Pubitemid 351171405)
34. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet. 2006 ; 14: 364-371
35. Rood MJ, van Krugten MV, Zanelli E, et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000 ; 43: 129-134 (Pubitemid 30368221)
36. Morgan BP, Walport MJ. Complement deficiency and disease. Immunol Today. 1991 ; 12: 301-306
37. Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford). 2000 ; 39: 133-141 (Pubitemid 30139345)
38. Steenvoorden MM, van der , Helm-van Mil AH, Stoeken G, et al. The RAGE G82S polymorphism is not associated with rheumatoid arthritis independently of HLA-DRB1*0401. Rheumatology (Oxford). 2006 ; 45: 488-490
39. Gaens KH, Ferreira I, van der , Kallen CJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009 ; 94: 5174-5180
40. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005 ; 16: 2363-2372 (Pubitemid 41725054)
41. Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res. 2005 ; 70: 137-141 (Pubitemid 41586467)
42. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008 ; 22: 3716-3727
43. Poirier O, Nicaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes. 2001 ; 50: 1214-1218 (Pubitemid 32374557)